(Q38047525)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23021557%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23021557%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23021557%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Brandon L Pierce

series ordinal

1

1 reference

27 August 2017

publication date

1 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23021557%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23021557%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23021557%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23021557%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

735-743

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23021557%20AND%20SRC:MED&resulttype=core&format=json

Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002.

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes mellitus type 2 - an independent risk factor for cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

A meta-analysis of diabetes mellitus and the risk of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes mellitus and risk of prostate cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Association of diabetes with prostate cancer risk in the multiethnic cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

The protective effect of diabetes mellitus against prostate cancer: role of sex hormones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes and risk of incident cancer: a large population-based cohort study in Israel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes mellitus and prostate cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

The metabolic syndrome and risk of prostate cancer in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes and risk of prostate cancer: a study using the National Health Insurance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Reduced risk of prostate cancer among patients with diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes Mellitus and the Risk of Prostate Cancer in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes and the risk of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes mellitus and risk of prostate cancer (United States).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

History of diabetes mellitus and risk of prostate cancer in physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes and Risk of Prostate Cancer in a Prospective Cohort of US Men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Glycemic status and risk of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Genetic susceptibility to type 2 diabetes is associated with reduced prostate cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

No association of type 2 diabetes risk variants and prostate cancer risk: the multiethnic cohort and PAGE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

HNF1B and JAZF1 genes, diabetes, and prostate cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Serum prostate-specific antigen levels in men with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Associations Between Diabetes and Clinical Markers of Benign Prostatic Hyperplasia Among Community-Dwelling Black and White Men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes and prostate cancer risk in the REDUCE trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Obesity and prostate cancer: making sense out of apparently conflicting data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Influence of obesity on the incidence and treatment of genitourinary malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms--what do we know?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

The influence of prostate size on cancer detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Normal histology of the prostate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

The association of diabetes and positive prostate biopsy in a US veteran population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi (≥ 12)-core prostate biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Diabetes, cancer, and metformin: connections of metabolism and cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Metformin and the incidence of prostate cancer in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Cancer risks in thiazolidinedione users compared to other anti-diabetic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Use of thiazolidinediones does not affect prostate-specific antigen levels in men with diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Cohort study of pioglitazone and cancer incidence in patients with diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Antidiabetic Medication and Prostate Cancer Risk: A Population-based Case-Control Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Five stages of evolving beta-cell dysfunction during progression to diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Association between C-peptide concentration and prostate cancer incidence in the CLUE II cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

The association between body size, prostate volume and prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Prediagnostic C-peptide and risk of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Androgen and prostate cancer: is the hypothesis dead?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Population differences in the testosterone levels of young men are associated with prostate cancer disparities in older men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Hormonal profile of diabetic men and the potential link to prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

IGFs and IGFBPs: role in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Why does diabetes offer protective effects against prostate cancer? The possible role of its microvascular complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Are microvascular complications of diabetes mellitus really associated with prostate cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

Does pre-existing diabetes affect prostate cancer prognosis? A systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.008

10.1016/J.UROLONC.2012.07.008

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23021557%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference